Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial

PURPOSE: Metastatic colorectal cancers (mCRCs) assigned to the transit-amplifying (TA) CRCAssigner subtype are more sensitive to anti–epidermal growth factor receptor (EGFR) therapy. We evaluated the association between the intratumoral presence of TA signature (TA-high/TA-low, dubbed as TA-ness cla...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontana, Elisa, Nyamundanda, Gift, Cunningham, David, Tu, Dongsheng, Cheang, Maggie C.U., Jonker, Derek J., Siu, Lillian L., Sclafani, Francesco, Eason, Katherine, Ragulan, Chanthirika, Bali, Maria Antonietta, Hulkki-Wilson, Sanna, Loree, Jonathan M., Waring, Paul M., Giordano, Mirella, Lawrence, Patrick, Rodrigues, Daniel Nava, Begum, Ruwaida, Shapiro, Jeremy D., Price, Timothy J., Cremolini, Chiara, Starling, Naureen, Pietrantonio, Filippo, Trusolino, Livio, O’Callaghan, Christopher J., Sadanandam, Anguraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529528/
https://www.ncbi.nlm.nih.gov/pubmed/33015526
http://dx.doi.org/10.1200/PO.20.00050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529528/
https://www.ncbi.nlm.nih.gov/pubmed/33015526
http://dx.doi.org/10.1200/PO.20.00050

Ejemplares similares